{"schema_version":"secwatch.filing_event.v1","accession":"0001683168-23-003203","form_type":"8-K","ticker":"XBIO","cik":"0001534525","company_name":"Xenetic Biosciences, Inc.","filed_at":"2023-05-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.305332+00:00","generated_at":"2026-06-15T04:04:52.547447+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Xenetic Biosciences Q1 net loss $0.9M; cash $12M; Takeda royalties up 55.7%","bullets":["Net loss of $0.9M for Q1 2023; R&D expenses down 46% to $0.6M from $1.1M.","Royalty payments from Takeda sublicense increased 55.7% to $0.6M.","Ended quarter with $12.0M cash; advancing DNase oncology program.","Entered collaboration with Scripps Research Institute for DNase and CAR T programs.","Appointed Scott N. Cullison and Reid P. Bissonnette to support DNase platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-23-003203","json":"https://secwatch.observer/filing/0001683168-23-003203.json","markdown":"https://secwatch.observer/filing/0001683168-23-003203.md","text":"https://secwatch.observer/filing/0001683168-23-003203.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1534525/000168316823003203/0001683168-23-003203-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1534525/000168316823003203/xenetic_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T04:04:52.547447+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9df2fa8417156635ed475bee34ff07d2e69f113e","claim":"Xenetic Biosciences, Inc. reported three months ended March 31, 2023 results: net income approximately $0.9 million.","evidence_excerpt":"Net loss for the quarter ended March 31, 2023 was approximately $0.9 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1534525/000168316823003203/0001683168-23-003203-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended March 31, 2023"},{"label":"Net income","value":"approximately $0.9 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}